Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "COPD"

83 News Found

Lupin to use Honeywell’s HFO technology in inhalers
News | May 21, 2025

Lupin to use Honeywell’s HFO technology in inhalers

Lupin is set to become first Indian company to fully integrate Honeywell’s Solstice® Air in its respiratory inhalers at scale, redefining respiratory care with near-zero global warming potential propellants


AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma
Clinical Trials | May 03, 2025

AstraZeneca’s Breztri met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease


ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease
News | April 17, 2025

ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74


Aerogen opens India HQ in New Delhi
News | March 20, 2025

Aerogen opens India HQ in New Delhi

The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India


Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
Drug Approval | September 06, 2024

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug


GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s  CHMP opinion for adults aged 50-59
Drug Approval | July 30, 2024

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024


USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Clinical Trials | June 14, 2024

USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes


Zydus receives final approval from USFDA for Theophylline ER Tablets
Drug Approval | May 25, 2024

Zydus receives final approval from USFDA for Theophylline ER Tablets

Theophylline is used to treat asthma and chronic obstructive pulmonary disease